Vitamin B5 Derivative Shows Early Promise Against Psoriasis
Pantethine reduced psoriasis in mice and reportedly improved human symptoms, linking immune inflammation to cholesterol production.
Summary
Pantethine, a supplement derived from vitamin B5, may help reduce the overactive immune response behind psoriasis. Researchers in China found elevated levels of enzymes called Vanins in immune cells from patients with psoriasis and other autoimmune diseases. Reducing these enzymes made the cells less active, and a Vanin-blocking drug prevented psoriasis in mice. The article also reports that pantethine prevented psoriasis in mice and improved symptoms in a small human trial. The proposed connection involves cholesterol production, which can influence immune activity. These findings suggest a potential treatment strategy, not proof that an available supplement reliably treats psoriasis. The supplied article is incomplete and gives no trial size, dosing, numerical benefits, or detailed safety results. Discuss supplements with a dermatologist rather than replacing established treatment.
Detailed Summary
Pantethine, a supplement derived from vitamin B5, may offer a new way to reduce psoriasis inflammation. Psoriasis involves an overactive immune response that produces persistent skin symptoms. Research summarized by Rockefeller University Press suggests that changing cholesterol production inside immune cells could help control this response, connecting cellular metabolism with an inflammatory disease that can substantially affect quality of life.
Researchers in China found unusually high levels of enzymes called Vanins in dendritic cells from patients with psoriasis and other autoimmune diseases. These immune cells normally coordinate defenses by presenting potential threats to T cells and releasing inflammatory signals. Reducing Vanin levels made dendritic cells less active and less able to stimulate T cells, suggesting a potential target for treatment.
A drug that inhibited Vanins prevented psoriasis from developing in mice. The article also reports that pantethine prevented psoriasis in mice and improved symptoms in a small human trial. Vanins help process pantethine into vitamin B5. Because pantethine can reduce cholesterol production, the findings point toward a possible link between cholesterol handling and the immune activity that drives skin inflammation.
For readers, the practical message is not to replace established psoriasis treatments with a supplement. Rather, the study identifies a promising approach that deserves further testing. Anyone considering pantethine should discuss it with a dermatologist, particularly when already using prescription therapies. The supplied article does not establish an effective dose, treatment duration, or which patients might be likely to benefit.
Important uncertainties remain. The supplied text ends abruptly and provides no human trial size, comparison group, numerical results, or detailed safety findings. Preventing experimentally induced disease in mice does not establish effectiveness against established psoriasis in humans. The primary Journal of Experimental Medicine paper should be checked for study design, adverse effects, and whether benefits persist over longer treatment periods.
Key Findings
- Researchers found elevated Vanin enzymes in dendritic cells from patients with psoriasis and other autoimmune diseases.
- Reducing Vanin levels dampened dendritic cell activity and their ability to stimulate T cells.
- Both Vanin inhibition and pantethine reportedly prevented psoriasis in mice; prevention does not establish treatment effectiveness in humans.
- A small human trial reportedly showed symptom improvement, but the supplied text omits numerical results, dosing, and safety details.
- Discuss pantethine with a dermatologist before use; these preliminary findings do not justify replacing established psoriasis treatment.
Methodology
This is a ScienceDaily research news report sourced to Rockefeller University Press, describing research published in the Journal of Experimental Medicine. The reported evidence combines patient immune-cell observations, laboratory experiments, mouse studies, and a small human trial; the primary paper was not supplied.
Study Limitations
The supplied article ends mid-sentence and omits human trial size, randomization, controls, effect sizes, dosing, and adverse events. Mouse prevention findings may not translate into treatment benefits for established human disease, and the primary paper is needed to assess clinical reliability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: